%0 Journal Article
%T Impact of CD34 positive cell dose in donor graft on the outcomes after haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide - A retrospective single-center study with a Japanese cohort.
%A Maruyama Y
%A Nishikii H
%A Kurita N
%A Sakamoto T
%A Hattori K
%A Suehara Y
%A Yokoyama Y
%A Kato T
%A Obara N
%A Sakata-Yanagimoto M
%A Chiba S
%J Blood Cells Mol Dis
%V 105
%N 0
%D 2024 03 30
%M 38199143
%F 2.372
%R 10.1016/j.bcmd.2023.102820
%X Haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) with post-transplant cyclophosphamide (PTCy) is an important therapeutic option for patients lacking an HLA-matched donor. However, the significance of CD34+ cell dose in grafts has not been fully elucidated.<BR>We aimed to explore the impact of CD34+ cell dose on outcomes after haplo-PBSCT with PTCy.<BR>We retrospectively investigated 111 consecutive patients who underwent haplo-PBSCT with PTCy or HLA-matched PBSCT from related donors.<BR>There were no statistically significant differences in 3-year overall survival (p = 0.559) or progression-free survival (p = 0.974) between haplo-PBSCT and matched PBSCT. Delayed neutrophil engraftment and a lower incidence of graft-versus-host disease were observed in haplo-PBSCT. The median dose of CD34+ cells was 4.9 × 106 /kg in 57 haplo-PBSCT and 4.5 × 106 /kg in 54 matched PBSCTs. Importantly, patients who underwent haplo-PBSCT with the administration of CD34+ cell at a dose of ≥4.0 × 106 /kg significantly had improved OS (p = 0.015) and decreased incidence of disease relapse (p = 0.001) without increasing incidence of GVHD.<BR>Our data suggest that a higher dose of CD34+ cells in haplo-PBSCT with PTCy positively impacts the outcomes without an increase of GVHD.